SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Northstar Global Services, Inc. (OTCMKTS:MDIN) has moved up by 50% after signing a deal, with a multi-billion dollar industry. The deal involves the company to develop genetically engineered bacteria to fight lactose intolerance. The stock of the company stood at $0.0009, which although is still triple zero land but means great improvement by the company. The product has been developed in partnership, with Celprogen Inc., and initial lab tests have shown great promise. It is believed that a single dose can free the patient of lactose intolerance for up to three months.

Lactose intolerance, like many other medical conditions, can cause minor to severe disruption in everyday life. The patent is aimed at developing something that is safe, efficient and cheap to ease the life of the patients. Seeing how the investors have reacted to the initial deal, it can be assumed that once the product is released the company stock would climb even higher.

The company had been previously marketing non-FDA approved products, which might have been the reason its stock is still at triple zero. However, the CEO of the company assured the investors that this move is just another step towards the company moving towards FDA approved products. The most interesting part for the shareholders was that no capital or free trading equity were used to acquire the patent. Instead, the firm used restricted shares of lockup periods up to one year while utilizing the capital to fund its inventory.

It seems that Northstar Global Services, Inc. (OTCMKTS:MDIN)’s decision to make reforms in management and strategy has worked out well for the company, since this is their first signing right after the new change. The company is now aiming at generating revenue and has appointed a new CEO, Brandon Dean, whose main target for the company is generation of substantial revenues. The organization also plans to rid itself of distributors marketing its products and take the additional responsibilities itself. The organization is also trying to move away from costly distribution companies and moving towards gaining shelf space of its own.

SHARE
Previous articlePharmacyte Biotech Inc (OTCMKTS:PMCB) Keeps on Improving With Luck on its Side
Next articleOSL Holdings Inc (OTCMKTS:OSLH) Decides To Go Against Reverse Stock Split
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.